See every side of every news story
Published Centennial, United StatesUpdated

ALLOSOURCE® ANNOUNCES 200TH IMPLANT OF ACECONNEX® PRE-SUTURED FASCIA DEVICE FOR HIP LABRAL RECONSTRUCTION AND AUGMENTATION

  • AlloSource announced the 200th implant of AceConnex Pre-Sutured Fascia for hip labral reconstruction and augmentation, making it the only 510 cleared pre-sutured fascia allograft in this field.
  • AceConnex minimizes variability compared to traditional methods, simplifying the surgical process by being ready-to-use and eliminating the need for in-operating room suturing.
  • Dr. Andrew Jimenez stated that AceConnex addresses unmet needs for surgeons performing hip labral procedures, providing quality and consistency.
  • Dean Elliott, AlloSource President and CEO, emphasized that reaching the 200-implant milestone supports their goal of innovating surgical solutions for complex hip arthroscopy procedures.
Insights by Ground AI
Does this summary seem wrong?

21 Articles

All
Left
1
Center
11
Right
Napa Valley RegisterNapa Valley Register
+19 Reposted by 19 other sources
Center

ALLOSOURCE® ANNOUNCES 200TH IMPLANT OF ACECONNEX® PRE-SUTURED FASCIA DEVICE FOR HIP LABRAL RECONSTRUCTION AND AUGMENTATION

CENTENNIAL, Colo., March 27, 2025 /PRNewswire/ -- AlloSource, a life sciences organization that helps restore patient functionality by transforming the gift of human tissue donation into enhanced medical products, today announced the 200th implant of AceConnex Pre-Sutured Fascia. The device…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 92% of the sources are Center
92% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Ortho Spine News | Your Trusted Voice for Medical Device Industry Ortho News broke the news in on Thursday, March 27, 2025.
Sources are mostly out of United States (4)

Similar News Topics

You have read 5 out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

Our use of cookies
Unlike other news sites, we do not share or sell your data to third-parties for targeted ads.
By continuing to use our application or website, you agree to our Terms of Service and Privacy Policy.